Sector News

Bayer CEO happy to have fair outcomes-based pricing

December 4, 2014
Life sciences
Outcomes-based pricing holds no fears for Marijn Dekkers but the Bayer chief executive has urged governments to level the playing field when comparing old drugs with innovative products.
 
At the German major’s Perspective on Innovation meeting in Leverkusen, Dr Dekkers (pictured) told PharmaTimes that in terms of realigning payment mechanisms around health outcomes is perfectly reasonable. “We are all for only getting paid for really good drugs,” he said, adding that as an innovative company “we have the ability to come up with treatments better than those on the market”.
 
Dr Dekkers went on to say “it is okay to be tested on that in the process of price-setting, that is fine, we should only be paid for the value we bring”. However he did add one important caveat.
 
He noted that in no other industry does a product’s price drop 80% when it goes off-patent, the key sticking-point when reimbursement issues come up. “When we have a new drug that is significantly better than the previous drug but the previous drug just went generic, we are compared to the 20% price, not the 100% price”.
 
Dr Dekkers said that when one uses the 20% (i.e. generic) price for comparisons, it is hard to show continuously improvement of new drugs even though they are significantly better than older ones. It is “a huge dilemma [and] if we don’t solve it we will take away the economic motivation” for high-risk innovative projects.
 
Volkswagen Beetle analogy
 
He then gave PharmaTimes an analogy with cars, saying that “if the automotive industry have patents like we have, we would all still be driving around in Volkswagen Beetles from the 60s. All the innovations and continuous improvements VW has made would not have justified the price differential”.
 
Dr Dekkers was upbeat at the meeting, noting that in the pharmaceuticals segment, Bayer has successfully completed 25 Phase III clinical studies since 2010 and emphasised the strength of its pipeline (more on this to follow on PharmaTimes).
 
He also highlighted the firm’s over-the-counter business, ranked number two in the world after acquiring the consumer care business of Merck & Co. When asked why an innovative company was focusing on OTC, Dr Dekkers said “we need diversifaction as a buffer…we don’t have to be sexy all the time, more selective sexiness”.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach